Sodium Bicarbonate Injection · 3,481 days since initial FDA posting
Brand: SODIUM BICARBONATE
FDA lists Sodium Bicarbonate Injection as Active Shortage (Hospira, Inc., a Pfizer Company).
Availability on file: Unavailable
Sodium Bicarbonate Injection: Active Shortage
Unavailable Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Sodium Bicarbonate Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)
- Package NDC
- 0409-6625-35
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Mar 1, 2017
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Endocrinology/Metabolism, Gastroenterology, Pediatric
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay
Nearby, Other Sodium Shortage Records
Sodium Bicarbonate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Bicarbonate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
FDA reason on file: Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay. General shortage guidance lives on the tracker hub.